Iomeron (Iomeprol)

Iomeprol contains a high concentration of iodine atoms that absorb X‑ray photons. When injected intra‑arterially or intravenously, the iodine remains in the vascular compartment, creating a temporary difference in X‑ray attenuation between blood‑filled structures and surrounding tissues, which results in clearer, more detailed images.

The dose of Iomeron is determined by the prescribing physician based on the specific imaging study, patient weight, renal function, and clinical protocol. Healthcare professionals calculate the appropriate volume and concentration to achieve optimal contrast enhancement while minimizing risk.

Iomeron is classified as pregnancy category B, indicating that animal studies have not shown risk but there are no adequate human studies. It should be used only if the diagnostic benefit justifies potential exposure. Limited data are available for breastfeeding; clinicians should weigh benefits against possible infant exposure.

To order Iomeron, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if required), and necessary import documentation.

Iomeron is a non‑ionic, low‑osmolality iodinated contrast medium, offering a favorable safety profile compared with older high‑osmolality agents. It provides comparable image quality to other modern non‑ionic agents while reducing the incidence of discomfort and adverse reactions, making it a preferred choice for many radiology departments.

Iomeron should be stored at ambient temperature, below 25 °C, in its original sealed container. Protect the solution from direct sunlight, moisture, and freezing. Do not shake the vial vigorously; gently invert if mixing is required before administration.

Iomeron is supplied as a sterile solution for injection and is administered intravenously or intra‑arterially by a qualified healthcare professional. The injection rate and total volume are tailored to the imaging protocol and patient characteristics to achieve optimal contrast enhancement.

The most serious risks include severe allergic or anaphylactoid reactions, acute renal impairment, and cardiovascular collapse such as severe hypotension. Patients with known iodine allergy, compromised kidney function, or uncontrolled thyroid disease require careful assessment before use.

Iomeron should be avoided in patients with a documented severe hypersensitivity to iodinated contrast media, uncontrolled hyperthyroidism, or those who are unable to undergo emergency treatment for anaphylaxis. Caution is also advised for patients with severe renal insufficiency or those on contraindicated medications.